Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00063388
Status:
COMPLETED
Last Update Posted:
2010-04-12
First Post:
2003-06-25
Brief Title:
Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase II Trial of Cetuximab C225 as Therapy for Recurrent Non-Small Cell Lung Cancer NSCLC
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Determine tumor response rate and time to disease progression survival and safety in total populations
Detailed Description:
To determine the tumor response rate and time to disease progression survival and safety in the EGFR-positive EGFR-negative and total populations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None